Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro phenotypic susceptibility of HIV-1 non-group M to CCR5 inhibitor (maraviroc): TROPI-CO study.

Microbiology spectrum - 2 Jul 2024

Gracias Ségolène, El Yaalaoui Ikrame, Visseaux Benoît, Charpentier Charlotte, Descamps Diane, Martin Charlène, Lermechain Fanny, Plantier Jean-Christophe, Alessandri-Gradt Elodie

Abstract excerpt

The susceptibility of genetically divergent HIV-1 strains (HIV-1 non-M) from groups O, N, and P to the CCR5 co-receptor antagonist, maraviroc (MVC), was investigated among a large panel of 45 clinical strains, representative of the viral genetic diversity. The results were compared to the reference strains of HIV-1 group M (HIV-1/M) with known tropism. Among the non-M strains, a wide range of phenotypic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to CCR5 Receptor Antagonists

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cyclohexanes

Share to HIV Fusion Inhibitors

Share to Inhibitory Concentration 50

Share to Receptors, CCR5

Share to Triazoles

Share to Viral Tropism

Source

Open in PubMed Open full text

Identifiers

PMID: 38809042
DOI: 10.1128/spectrum.03895-23
PMCID: PMC11218461

Genes

CCR5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro phenotypic susceptibility of HIV-1 non-group M to CCR5 inhibitor (maraviroc): TROPI-CO study.PMID 38809042Read ↗

<i>In vitro</i> phenotypic susceptibility of HIV-1 non-group M to CCR5 inhibitor (Maraviroc): TROPI-CO studySemantic proximity Read ↗

Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.Semantic proximity Read ↗

Phenotypic co-receptor tropism and Maraviroc sensitivity in HIV-1 subtype C from East Africa.Semantic proximity Read ↗

Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages.Semantic proximity Read ↗

In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.Semantic proximity Read ↗

HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitroSemantic proximity Read ↗

Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029.Semantic proximity Read ↗

Genotypic tropism testing: evidence-based or leap of faith?Semantic proximity Read ↗

Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.Semantic proximity Read ↗

HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs.Semantic proximity Read ↗

HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitorsSemantic proximity Read ↗

HIV-1 subtype C predicted co-receptor tropism in Africa: an individual sequence level meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.